The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kostyuk G.P.

Serbsky Federal Medical Research Center for Psychiatry and Narcology, Moscow, Russia, Institute of Medical and Social Technologies, Moscow, Russia, Alekseev Psychiatric Clinical Hospital №1, Moscow, Russia

Zakharova N.V.

I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg, Russia

Reznik A.M.

Gosudarstvennyĭ institut usovershenstvovaniia vracheĭ Ministerstva oborony RF, Moskva

Surkova E.I.

OOO «Mikrotesty v biologii, meditsine i veterinarii», Moskva, Rossija

Ilinsky V.V.

Genotek Inc., Moscow;
Vavilov Institute of General Genetics Russian Academy of Sciences, Moscow

Perspectives of the use of pharmacogenetic tests in neurology and psychiatry

Authors:

Kostyuk G.P., Zakharova N.V., Reznik A.M., Surkova E.I., Ilinsky V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9): 131‑135

DOI: 10.17116/jnevro2019119091131

Read: 2858 times

Download PDF (RU)
Contact the author
Table of contents

PERSPECTIVES OF THE USE OF PHARMACOGENETIC TESTS IN NEUROLOGY AND PSYCHIATRY
PERSPECTIVES OF THE USE OF PHARMACOGENETIC TESTS IN NEUROLOGY AND PSYCHIATRY

To cite this article:

Kostyuk GP, Zakharova NV, Reznik AM, Surkova EI, Ilinsky VV. Perspectives of the use of pharmacogenetic tests in neurology and psychiatry. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):131‑135. (In Russ.)
https://doi.org/10.17116/jnevro2019119091131

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
The asso­ciation of NOS1AP gene poly­morphisms with the dura­tion of the QT inte­rval in patients with schi­zophrenia receiving anti­psychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Review of the main provisions of the upda­ted clinical reco­mmendations “Noise-induced hearing loss”. Russian Bulletin of Otorhinolaryngology. 2025;(2):88-93
Chro­nic obstructive pulmonary disease (COPD 2024). Clinical guidelines (short version). Journal of Respiratory Medi­cine. 2025;(2):5-16
Clinical Deci­sions in the Abse­nce of Evidence: Expert’s Panel Reco­mmendations for the Mana­gement of Chro­nic Venous Disease and Supe­rficial Thro­mbophlebitis. Journal of Venous Diso­rders. 2025;(2):126-140
Changes in diagnosis-related group payment model in the Russian Fede­ration in 2025. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):18-30
Approaches to the digi­tization of clinical guidelines. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):39-47
Unre­solved questions of recu­rrent implantation failure. Russian Journal of Human Reproduction. 2025;(3):42-47
Neuropathic pain in chro­nic inflammatory demye­linating poly­neuropathies: analysis of 64 cases. Russian Journal of Pain. 2025;(2):45-53
Abstract:

The review is devoted to the analysis of the current state of pharmacogenetic research and their use in psychiatric practice. The main genes responsible for the pharmacodynamics and pharmacokinetics of drugs used in psychiatry are listed. Foreign pharmacogenetic clinical recommendations and progress on their implementation in medical practice in various countries of Europe and the USA are analyzed. The need to create Russian clinical guidelines on pharmacogenomics to improve the effectiveness of patient care and to implement a personalized approach to therapy is discussed.

Keywords:

pharmacogenomics
pharmacogenetics
antidepressants
antipsychotics
psychopharmacotherapy
clinical guidelines

Authors:

Kostyuk G.P.

Serbsky Federal Medical Research Center for Psychiatry and Narcology, Moscow, Russia, Institute of Medical and Social Technologies, Moscow, Russia, Alekseev Psychiatric Clinical Hospital №1, Moscow, Russia

Zakharova N.V.

I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg, Russia

Reznik A.M.

Gosudarstvennyĭ institut usovershenstvovaniia vracheĭ Ministerstva oborony RF, Moskva

Surkova E.I.

OOO «Mikrotesty v biologii, meditsine i veterinarii», Moskva, Rossija

Ilinsky V.V.

Genotek Inc., Moscow;
Vavilov Institute of General Genetics Russian Academy of Sciences, Moscow

Close metadata

References:

  1. Nasyrova RF, Ivanov MV, Neznanov NG. Vvedenie v psihofarmakogenetiku. SPb.: Izdatel’stkij centr SPb NIPNI im. V.M. Bekhtereva; 2015. (In Russ.)
  2. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343-350. https://doi.org/10.1038/nature15817
  3. Pirmohamed M. Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol. 2001;52(4):345-347.
  4. Arwood MJ, Chumnumwat S, Cavallari LH, Nutescu EA, Duarte JD. Implementing pharmacogenomics at your institution: establishment and overcoming Implementation challenges. Clin Transl Sci. 2016;9(5):233-245. https://doi.org/10.1111/cts.12404
  5. Hughes D, Andersson DI. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet. 2015;16(8):459-471. Epub 2015 Jul 7. https://doi.org/10.1038/nrg3922
  6. Tonozzi TR, Braunstein GD, Kammesheidt A, Curran C, Golshan S, Kelsoe J. Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study. Pharmacogenomics. 2018;19(15):1169-1179. https://doi.org/10.2217/pgs-2018-0088
  7. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
  8. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
  9. Willeit M, Praschak-Rieder N. Imaging the effects of genetic polymorphisms on radioligand binding in the living human brain: A review on genetic neuroreceptor imaging of monoaminergic systems in psychiatry. Neuroimage. 2010;53(3):878-892. https://doi.org/10.1016/j.neuroimage.2010.04.030
  10. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15(5):473-500. https://doi.org/10.1038/mp.2008.116
  11. O’Connell CP, Goldstein-Piekarski AN, Nemeroff CB, Schatzberg AF, Debattista C, Carrillo-Roa T, Binder EB, Dunlop BW, Craighead WE, Mayberg HS, Williams LM. Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. Am J of Psychiatry. 175(3):251-261.
  12. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6-13.
  13. Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician. 2008;77(11):1553-1560.
  14. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79(1):103-113.
  15. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Müller DJ, Gaedigk A, Stingl JC; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402-408. https://doi.org/10.1038/clpt.2013.2
  16. O’Brien FE, Clarke G, Dinan TG, Cryan JF, Griffin BT. Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability. Int J Neuropsychopharmacol. 2013;16(10):2259-2272. https://doi.org/10.1017/S1461145713000692
  17. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM Jr. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics. 2010;20(8):467-475. https://doi.org/10.1097/FPC.0b013e32833b593a
  18. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Pütz B, Binder EB, Müller-Myhsok B, Holsboer F. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57(2):203-209. https://doi.org/10.1016/j.neuron.2007.11.017
  19. Bousman CA, Müller DJ, Ng CH, Byron K, Berk M, Singh AB. Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study. Pharmacogenet Genomics. 2017;27(1):1-6.
  20. Bradley P, Shiekh M, Mehra V, Vrbicky K, Layle S, Olson MC, Maciel A, Cullors A, Garces JA, Lukowiak AA. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. J Psychiatr Res. 2018;96:100-107. https://doi.org/10.1016/j.jpsychires.2017.09.024
  21. Zhou ZW, Chen XW, Sneed KB, Yang YX, Zhang X, He ZX, Chow K, Yang T, Duan W, Zhou SF.Clinical association between pharmacogenomics and adverse drug reactions. Drugs. 2015;75(6):589-631. https://doi.org/10.1007/s40265-015-0375-0
  22. Ramsey T, Griffin E, Liu Q, Brennan MD, Vaishnavi S. Use of Pharmacogenetic Testing in Routine Clinical Practice Improves Outcomes for Psychiatry Patients? J Psychiatry. 2016;19:377. https://doi.org/10.4172/2378-5756.1000377
  23. Dokukina TV, Starcev AI, Mahrov MV, Gajdukevich IV, Golubeva TS, Gilep AA, Sheremet EA, Shamruk IV, Pinchuk AS, Marchuk SA, Hlebokazov FP, Misyuk NN Sravnitel'naya effektivnost' personalizacii terapii antikonvul'santami i antipsihotikami na osnovanii farmakogeneticheskogo testirovaniya. Epilepsiya i paroksizmal'nye sostoyaniya. 2016;2:6-13. (In Russ.)
  24. Johansen Taber KA, Dickinson BD. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmgenomics Pers Med. 2014;7:145-162. eCollection 2014. https://doi.org/10.2147/PGPM.S63715
  25. Hinderer M, Boeker M, Wagner SA, Lablans M, Newe S, Hülsemann JL, Neumaier M, Binder H, Renz H, Acker T, Prokosch HU, Sedlmayr M. Integrating clinical decision support systems for pharmacogenomic testing into clinical routine — a scoping review of designs of user-system interactions in recent system development. BMC Med Inform Decis Mak. 2017;17(1):81. https://doi.org/10.1186/s12911-017-0480-y
  26. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Therapeut. 2011;89(3):387-391.
  27. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Hicks JK, Schwab M, Klein TE. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Therapeut. 2013;93(4):324-325.
  28. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Therapeut. 2011;90(2):328-332.
  29. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update. Clin Pharmacol Therapeut. 2013;94(3):317-323.
  30. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Therapeut. 2011;90(4):625-629.
  31. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Therapeut. 2012;91(2):321-326. [PMC free article] [PubMed].
  32. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Therapeut. 2012;91(4):734-738.
  33. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Therapeut. 2012;92(1):112-117.
  34. Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MT. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Therapeut. 2013;93(2):153-158.
  35. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Muller DJ, Gaedigk A, Stingl JC. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Therapeut. 2013;93(5):402-408.
  36. Leckband SG, Kelsoe JR, Dunnenberger HM, George AL Jr, Tran E, Berger R, Muller DJ, Whirl-Carrillo M, Caudle KE, Pirmohamed M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing. Clin Pharmacol Therapeut. 2013;94(3):324-328.
  37. Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O’Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR; Pharmacogenomics Research Network Translational Pharmacogenetics Program.The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems. Clin Pharmacol Ther. 2017;102(3):502-510. Epub 2017 Jun 9. https://doi.org/10.1002/cpt.630
  38. Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, McDonagh EM, Sangkuhl K, Thorn CF, Schwab M, Agundez JA, Freimuth RR, Huser V, Lee MT, Iwuchukwu OF, Crews KR, Scott SA, Wadelius M, Swen JJ, Tyndale RF, Stein CM, Roden D, Relling MV, Williams MS, Johnson SG. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2):209-217.
  39. Bousman C, Maruf AA, Müller DJ. Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel. Curr Opin Psychiatry. 2018. https://doi.org/10.1097/YCO.0000000000000465
  40. Saldivar JS, Taylor D, Sugarman EA, Cullors A, Garces JA, Oades K, Centeno J. Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility. Pharmgenomics Pers Med. 2016;9:1-6. eCollection 2016. https://doi.org/10.2147/PGPM.S93480
  41. Sugarman EA, Cullors A, Centeno J, Taylor D. Contribution of Pharmacogenetic Testing to Modeled Medication Change Recommendations in a Long-Term Care Population with Polypharmacy. Drugs Aging. 2016;33(12):929-936.
  42. Maciel A, Cullors A, Lukowiak AA, Garces J. Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings. Neuropsychiatr Dis Treat. 2018;14:225-230. eCollection 2018. https://doi.org/10.2147/NDT.S145046
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.